{"url":"https://lda.senate.gov/api/v1/filings/f4fdb6ab-367f-4c71-ad9d-7c2dfc8ff76e/","filing_uuid":"f4fdb6ab-367f-4c71-ad9d-7c2dfc8ff76e","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2016,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f4fdb6ab-367f-4c71-ad9d-7c2dfc8ff76e/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Joseph H. Gibson","dt_posted":"2017-01-23T10:06:12-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 Thirteenth Street, N.W.","registrant_address_2":"11th Floor South","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":400703107,"url":"https://lda.senate.gov/api/v1/registrants/400703107/","house_registrant_id":41536,"name":"THE GIBSON GROUP, LLC","description":"​Government Affairs Consulting Firm.","address_1":"601 Thirteenth Street, N.W.","address_2":"Suite B2 North","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JOSEPH GIBSON","contact_telephone":"+1 202-744-2827","dt_updated":"2026-07-07T10:31:17.598906-04:00"},"client":{"id":194408,"url":"https://lda.senate.gov/api/v1/clients/194408/","client_id":12,"name":"ENDO PHARMACEUTICALS INC.","general_description":"Speciality healthcare solutions company.","client_government_entity":false,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-03-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues relating to prescription drug abuse.\nIssues relating to incentives for tamper-resistant formulations.\nIssues relating to FDA approvals of new drugs and generic drugs.\nIssues related to the FDA.\nIssues related to Opioids.\nIssues relating to Medicare Part D rebates.\nHouse 21st Century Cures bill (Senate companion which includes NIH and FDA issues).\nH.R. 471/S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015.\nIssues relating to the labeling of generic drugs.\nIssues relating to CDC guidance for prescribing opioids.\nS. 2948 and H.R. 5748 - The Medicaid Generic Drug Price Fairness Act.\nIssues relating to products containing high doses of acetaminophen.\nIssues relating to the labeling of generic drugs.\nIssues relating to removal of FDA unapproved products from the market.\nH.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016.\nS.524 - To authorize the Attorney General and Secretary of Health and Human Services to award grants to address the national epidemics of prescription opioid abuse and heroin use, and to provide for the establishment of an inter-agency task force to review, modify, and update best practices for pain management and prescribing pain medication, and for other purposes.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54211,"prefix":"mr","prefix_display":"MR.","first_name":"JOSEPH","nickname":null,"middle_name":"H","last_name":"GIBSON","suffix":null,"suffix_display":null},"covered_position":"Counsel for Legislative & Intergovernmental Affairs Anti-Trust Division, DOJ 2001-2002; Chief Antitrust Counsel, House Judiciary Committee 1997-2001; Counsel, House Judiciary Committee 1995-1997","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues relating to incentives for life sciences research.\nH.R. 160: Protect Medical Innovation Act of 2015.\nTax treatment of inverted companies.\nTax issues in mergers and acquisitions of US firms.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54211,"prefix":"mr","prefix_display":"MR.","first_name":"JOSEPH","nickname":null,"middle_name":"H","last_name":"GIBSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Oversight of implementation of the America Invents Act.\nIssues relating to patent settlements.\nH.R. 9: The Innovation Act.\nS. 1137: Protecting American Talent and Entrepreneurship Act of 2015 (PATENT Act).\nIssues relating to misuse of the inter pares review process.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":54211,"prefix":"mr","prefix_display":"MR.","first_name":"JOSEPH","nickname":null,"middle_name":"H","last_name":"GIBSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}